Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season. Big pharma companies, including Johnson & Johnson (NYSE: JNJ) and Novartis AG (NYSE: NVS) reported forecast-beating results and issued positive guidance. Preannouncements from the space were also largely positive. Moderna, Inc.’s (NASDAQ: MRNA) buoyancy spilled over into the week. The … Source link
Read More »Fate of Biogen’s Stock Rides on Alzheimer’s Drug Decision
(Bloomberg) — For Biogen Inc., the Food and Drug Administration’s expected decision Monday on its Alzheimer’s drug is what a JPMorgan Chase & Co. analyst called “the mother of all binary events” — one that could send its shares veering sharply in either direction. If regulators give the company approval to market the drug, called aducanumab, the stock could surge to as much to $450, according to Wall Street analysts. Or it could tumble to $200 if the treatment is shot down,… Source link
Read More »